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A new type of VIP receptor was characterized in human SUP-T1 lymphoblasts. The order of potency of unlabeled pep- 
tides, in the presence of [iZSI]helodermin, was: helodermin(l-35)-NH, = helodermin(l-27)-NH, > helospectin > VIP 
= PHI > [D-Sefl]VIP > [D-As$]VIP > [D-His’]VIP 2 [D-Ala4]VIP p secretin = GRF. This specificity was distinct 
from that of all VIP receptors described so far in that: (i) the affinity for helodermin (Kd = 3 nM) was higher than that 
of VIP (Kd = 15 nM) and PHI (Kd = 20 nM); and (ii) position 4 played an important role in ligand binding. The labeled 
sites were likely to be functional receptors as adenylate cyclase in crude lymphoblastic membranes (200-10000 x g pellets) 
was stimulated by peptides, in the presence of GTP, with the following order of potency: helodermin(l-35)-NH, > helo- 
dermin(l-27)-NH, > helospectin = VIP = PHI. 
Helodermin receptor; Vasoactive intestinal peptide; (T-cell-derived culture line, SUP-Tl, Human) 
1. INTRODUCTION 
The neuropeptide VIP regulates T immune 
responses. Indeed, human blood T-lymphocytes 
possess high-affinity VIP receptors (& 0.24-0.47 
nM) and a highly sensitive VIP-responsive aden- 
ylate cyclase system [l-6]. In mice the density of 
VIP-binding sites on T-cells from secondary lym- 
phoid organs is much higher than in thymus which 
suggests that the expression of VIP receptors 
depends on T-cell maturation. In mouse and 
sheep, VIP and dibutyryl cyclic AMP modulate the 
migration of T-lymphocytes [7-lo]. Besides, VIP 
inhibits, probably via cyclic AMP, the pro- 
liferative response of T-lymphocytes to the 
mitogens Con A and phytohemagglutinin [7]. 
The human immunodeficiency virus (HIV), the 
causative agent of AIDS (acquired immune defi- 
ciency syndrome), penetrates human T4+ (CD& 
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helper/inducer T-lymphocytes after binding of the 
viral surface gp120 env glycoprotein with the cell 
surface 60 kDa antigenic marker T4 (CD4). This 
initiation of the infectious cycle is followed by 
virus endocytosis, reduced T-cell proliferative 
response, virus proliferation, and virus exocytosis 
by a process involving again fusion of gp120 with 
Tq at the cell surface [l 11. In T4+ cell cultures, HIV 
infection induces syncytium formation by cell-to- 
cell fusion through further gpl20-Td interactions. 
The resulting multinucleated giant cells are com- 
posed of both infected and uninfected T4+ cells 
recruited because the gp120 protein on the budding 
virion binds T4 receptors on uninfected cells. The 
syncytia balloon and the death of both infected 
and uninfected cells then follows [12-161. 
Pert and co-workers [17,18] claimed recently 
that the continuous epitope ASTTTNYT of gp120 
is the major attachment sequence to T4 receptors in 
human T-lymphocytes. This octapeptide (called 
peptide T because of its high threonine content) 
shows 5 sequence similarities (A-T-NYT) with the 
4-11 sequence of VIP so that the question arises 
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whether VIP receptors and the adenylate cyclase 
system are related to T4. If this were the case, the 
lymphotropic properties of HIV might result from 
the VIP-mimetic properties of gp120. Indeed, Pert 
et al. observed that peptide T blocks the adsorp- 
tion on the virion to its T4 receptor in human 
peripheral blood T4 cells and concluded that pep- 
tide T competes with gp120 for T4 binding because 
of the region in gp120 specified by peptide T. Un- 
fortunately, the T peptide sequence used by Pert et 
al. corresponds to a highly variable region of 
gp120 and, when tested by Sodroski et al. [19], ex- 
erts no effect on gp120 binding to SUP-T1 cells, a 
childhood T-cell lymphoma cell line (SUP-T1 = 
Stanford University Pediatric T-cell line 1) 
established from a pleural effusion of a lym- 
phoblastic lymphoma showing a chromosome 14 
inversion due to a break on the long (q) arm near 
the proximal portion [20]. 
At the Pasteur Institute of Brabant, the same 
SUP-T1 cell line is utilized for testing syncytium 
formation after AIDS invasion. We therefore 
decided to characterize the VIP receptors of this 
cell line and observed the existence of a new type 
of receptor with an affinity for helodermin 
5-7-times higher than that for VIP and PHI, our 
binding data on intact cells being compatible with 
the ability of the same peptides to stimulate 
adenylate cyclase in crude membranes. The lizard 
peptides helodermin and helospectin belong to the 
VIP-PHI-secretin-GRF family [21-231. Heloder- 
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min-like material is also present in normal mam- 
malian (including human) tissues [24,25], human 
medullary thyroid carcinomas 1261 and human 
pancreatic endocrine tumors [27]. The present data 
on human SUP-T1 lymphoblasts were unexpected 
as the potency of helodermin binding to VIP recep- 
tors [21,28] (and also secretin receptors in the rat 
pancreas [29]) had thus far been found to be 
weaker than that of VIP or secretin. 
2. MATERIALS AND METHODS 
Human lymphoblasts (SUP-T1 cell line) were cultured at 
37°C in RPM1 medium supplemented with 5% fetal calf serum. 
Stock cultures were transferred every 2 days in 2 vols of fresh 
medium. Cells were harvested by centrifugation at 600 x g for 
10 min and resuspended in assay buffer. This buffer was made 
of 100 mM Tris, 120 mM NaCl, 5 mM KCl, 1.2 mM MgSOd, 
15 mM CHpCOONa, 10 mM glucose, 1 mM EDTA and 1% 
bovine serum albumin, and the pH was adjusted to 7.4. 
Binding studies were conducted at 37°C in a final volume of 
0.12 ml in the presence of [lZSI]helodermin [28] and increasing 
concentrations of unlabeled peptides. The reaction was stopped 
by filtration through glass-fiber filters GF/C (Whatman, 
Maidstone, England) presoaked for 24 h in 0.05% 
polyethyleneimine in order to reduce nonspecific adsorption of 
tracer to the filter. Nonspecific binding was defined as binding 
in the presence of 1 PM unlabeled helodermin. 
To prepare crude membranes, lymphoblasts were pelleted at 
2O”C, resuspended in 1 mM NaHCOs @H 7.0) then dispersed 
in liquid nitrogen. After thawing and centrifugation at 200 x g 
for 10 min, the supernatant was centrifuged at 10000 x g for 
15 min at 4°C. The final pellet was resuspended in the same 
volume of homogenization medium and either tested im- 
mediately or stored at - 80°C until use. 
Adenylate cyclase activity was determined as previously 
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Fig.1. Kinetics of association (A), dissociation (B) and degradation (C) of [‘251]helodermin in the presence of SUP-T1 lymphoblasts. 
Experiments were conducted at 37°C as described in section 2. All results were the means of experiments performed in duplicate on 
three different preparations. 
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described [30]. Under all conditions tested cyclic AMP produc- 
tion was linear during the incubation period. 
Natural helodermin and natural helospectin were prepared as 
previously reported [31] from lizard venoms (Sigma, St Louis, 
MO), synthetic helodermin was provided by Dr J.P. Durieux 
(Novabiochem, Eiufelfingen, Switzerland), synthetic heloder- 
min analogues and fragments were gifts from Dr N. Yanaihara 
(Shizuoka College of Pharmacy, Shizuoka, Japan) and VIP, 
PHI, GRF and VIP analogues were prepared by Dr D.H. Coy 
(Tulane University School of Medicine, New Orleans, LA). 
Secretin was prepared by Dr W. Konig (Hoechst, Frankfurt am 
Main, FRG). All other reagents were of the highest grade 
available. 
3. RESULTS 
The specific binding of [1251]helodermin to SUP- 
Tl cells reached pseudoequilibrium after 60 to 
90 min (fig. 1A). Nonspecific binding represented 
20% of total binding. The dissociation rate of 
bound tracer was examined by chemical dilution 
after washing the labeled cells and their resuspen- 
sion in 10 vols of fresh buffer. The monophasic 
dissociation of the radioligand (f1/2 = 22 f 5 min, 
mean f SE of 3 determinations) suggested that the 
tracer labeled a single receptor population (fig.lB). 
Tracer degradation was extremely low as only 5% 
of the radioactivity offered was no longer 
precipitable by 10% trichloroacetic, after a 60 min 
incubation at 37°C in the presence of cells (fig.lC). 
Further experiments were therefore conducted 
over a 60 min incubation period. 
[i2’I]Helodermin binding was completely in- 
hibited by unlabeled helodermin (& = 3 nM), VIP 
(& = 15 nM) and PHI (& = 20 nM). Secretin and 
GRF were virtually ineffective (fig.2). The frag- 
ment helodermin( I-27)-NH2 and synthetic 
helodermin(l-35)-NH2 were equipotent o natural 
helodermin (fig.3, and not shown). Natural 
helospectin was slightly less potent than heloder- 
min (& = 10 nM) but more potent than VIP. The 
fragment helodermin(7-35)-NH2 recognized poor- 
ly the receptor and all other helodermin fragments 
tested were ineffective (fig.3). Four VIP analogues 
inhibited [‘2sI]helodermin binding (fig.4) with the 
following order of decreasing potency: VIP > [D- 
Ser2]VIP > [D-Asp3]VIP > [D-His’]VIP > [D- 
Ala4]VIP. This order differed clearly from that 
found for VIP receptors in rat pancreatic, hepatic 
and pituitary membranes [30]: VIP > [D- 
Ala4]VIP > [D-Asp31 VIP > [D-Ser2]VIP > [D- 
His’]VIP. 
[PEPTIDE CONCENTRATION] (log Ml 
Fig.2. Inhibition of [iz51]helodermin binding to SUP-T1 
lymphoblasts by natural helodermin, VIP, PHI, secretin and 
human GRF(l-29)-NHz. Incubation was conducted at 37°C 
during 60 min. Results are expressed in % of tracer bound and 
were the means of experiments performed in duplicate on three 
different preparations. 
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Fig.3. Inhibition of [‘251]helodermin binding to SUP-T1 
lymphoblasts by helodermin, helospectin and helodermin 
fragments (all peptides were amidated). Same methodology and 
representation as in fig.2. 
VIP 
[PEPTIDE CONCENTRATION] (log M) 
Fig.4. Inhibition of [‘ZSI]helodermin binding to SUP-T1 
lymphoblasts by helodermin, VIP and the VIP analogues [D- 
His’]VIP, ID-Ser’]VIP, [D-Asp’]VlP, and ID-Ala4]VIP. Same 
methodology and representation as in figs 2 and 3. 
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Helodermin(l-35)-NH2 and (l-27)-NHz, helo- 
spectin, VIP and PHI stimulated the adenylate 
cyclase activity of crude membranes from SUP-T1 
lymphoblasts in the presence of 10 FM GTP 
(fig.5). VIP and PHI were slightly less effective 
than the other peptides. 
4. DISCUSSION 
Our results demonstrated the presence, in 
human T-lymphoblasts (SUP-Tl), of receptors 
capable of recognizing peptides of the VIP family 
with a selectivity that had not previously been 
observed. Indeed, the decreasing order of potency 
of these peptides (figs 2-4) was: heloder- 
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Fig.5. Effect of increasing concentrations of helodermin(l-35)- 
NH+ helodermin(l-27)-NH2, helospectin(l-37), VIP and PHI 
on adenylate cyclase activity in crude membranes from SUP-T1 
lymphoblasts. The results were expressed in pmol cyclic AMP 
produced.min-*.mg protein- ‘. The data were the means of 
experiments performed in duplicate on three different 
preparations. 
min( I-35)-NH2 = helodermin( l -27)-NH2 > 
helospectin > VIP = PHI > [D-Ser’]VIP > [D- 
Asp3]VIP > [D-His’]VIP > [D-Ala4]VIP 9 
secretin = GRF, implying a unique selectivity pat- 
tern when compared to that found in all other VIP 
receptors previously characterized [21,28-301. The 
term ‘helodermin-affinity receptor’ can thus be 
proposed in this case. It is of interest to note that 
the amidated fragment helodermin(l-27)-NH2 was 
as active as helodermin(l-35)-NH2 but that the 
shorter amidated fragment helodermin( l-2 l)-NH2 
had completely lost the ability to recognize the 
receptors. However, the C-terminal sequence of 
helodermin(l-27) was not the only portion of the 
molecule involved in receptor recognition as 
helodermin(7-35)-NH2 showed very weak affinity 
only. As for the other peptides of the family, the 
whole molecule was probably required for proper 
receptor occupancy. Position 4 of the peptide was 
of particular interest in distinguishing between 
helodermin-affinity receptors and VIP receptors: 
[D-Ala4]VIP was lOO-fold less potent than VIP on 
the present helodermin-affinity receptors (fig.4) 
while being only 2-fold less potent than VIP on 
several VIP receptors [30]. 
[‘251]Helodermin binding sites in intact cells 
were likely to be functional receptors as the ap- 
parent & of helodermin(l-35)-NH2, heloder- 
min( l-27)-NH2, helospectin( l-37), VIP and PHI, 
required for half-maximal occupancy of these 
sites, correlated reasonably well with the concen- 
trations needed for half-maximal adenylate cyclase 
activation in crude membranes, in the presence of 
GTP. 
The presence of receptors for the VIP family of 
peptides on SUP-T1 cells derived from a T-cell 
lymphoma is not surprising as VIP receptors are 
present in human peripheral T-cell lymphocytes 
[l-6]. VIP also binds to another human lym- 
phoblastoid cell line (Molt 4b T, suppressor). The 
affinity of normal lymphocytic receptors for VIP 
ranges between 0.24 and 0.47 nM whereas that of 
Molt 4b T-lymphoblasts is 7.0-15 nM 132,331, a
value comparable to that observed by us in SUP- 
Tl cells. The helodermin-affinity receptors of 
SUP-T1 cells differ, however, from Molt 4b T- 
lymphoblast VIP receptors based on the relative 
potency of PHI and GRF. It is tempting to suggest 
that the new type of receptor in human SUP-T1 
lymphoblasts is either a transformed VIP receptor 
354 
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or a helodermin receptor revealed by malignancy 
that has not (yet) been identified in healthy tissues. 
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